THU0397 Increased Bone Mass and Bone Strength by Sclerostin Antibody (Scl-Ab) is Maintained by a RANKL Inhibitor in OVX Rats with Established Osteopenia

Background Some Scl-Ab-induced BMD gains gradually reversed after treatment discontinuation in rats. Objectives To examine if follow-up treatment with a RANKL inhibitor, OPG-Fc, would maintain Scl-Ab-induced bone mass gains in OVX rats. Methods Six-month-old OVX rats (2 months post-OVX) were treated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A299-A300
Hauptverfasser:	Ominsky, M., Li, X., Warmington, K., Niu, Q.-T., Asuncion, F., Dwyer, D., Grisanti, M., Han, C.-Y., Kostenuik, P., Stolina, M., Ke, H.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!